Entrada Therapeutics, Inc.

TRDASEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1689375

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue from Contract with Customer, Excluding Assessed Tax	$210.8M	$129.0M	$129.0M	—	—
Research and Development Expense	$125.3M	$99.9M	$66.6M	$35.9M	$21.1M
Operating Expenses	$163.8M	$132.2M	$97.2M	$51.1M	$26.7M
Operating Income (Loss)	$47.0M	-$3.2M	-$97.2M	-$51.1M	-$26.7M
Other Nonoperating Income (Expense)	$19.5M	$15.2M	$2.6M	-$31.0K	$144.0K
Income Tax Expense (Benefit)	$859.0K	$18.7M	$0.00	$0.00	$0.00
Net Income (Loss) Attributable to Parent	$65.6M	-$6.7M	-$94.6M	-$51.2M	-$26.5M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$526.3M	$469.2M	$252.1M	$305.8M	$43.5M
Assets, Current	$440.0M	$369.8M	$209.9M	$298.7M	$39.9M
Cash and Cash Equivalents, at Carrying Value	$101.2M	$67.6M	$45.2M	$291.1M	$39.0M
Liabilities	$97.6M	$226.8M	$39.5M	$7.1M	$3.4M
Liabilities, Current	$39.5M	$158.8M	$22.0M	$6.7M	$3.4M
Accounts Payable, Current	$4.3M	$3.3M	$6.0M	$706.0K	$1.6M
Stockholders' Equity Attributable to Parent	$242.4M	$212.6M	$298.7M	-$41.5M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$41.6M	$139.8M	-$93.8M	-$50.9M	-$25.6M
Net Cash Provided by (Used in) Investing Activities	-$27.8M	-$138.4M	-$148.7M	-$4.6M	-$2.3M
Net Cash Provided by (Used in) Financing Activities	$103.0M	$21.0M	$479.0K	$307.5M	$50.1M
Payments to Acquire Property, Plant, and Equipment	$3.2M	$5.6M	$2.9M	$4.6M	$2.3M

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)